GlassScriptPhysician profile
Melville J Ackerman
NPI 1598707580
$3,052.85
in general payments reported to CMS, 2019-2025
24 companies · $13.69 in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $442 · 2023: $956 · 2024: $1,503 · 2025: $13.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $830.57 | 2021-2024 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $537.17 | 2021-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $174.86 | 2023-2024 | Entyvio, Gattex |
| Genzyme Corporation | $174.00 | 2022-2024 | |
| Pfizer INC. | $154.72 | 2023-2024 | |
| Janssen Biotech, INC. | $146.86 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Qol Medical, LLC | $124.96 | 2021-2024 | Sucraid, Sucraid |
| Celgene Corporation | $123.29 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $108.78 | 2023-2024 | Dupixent |
| Lilly USA, LLC | $87.33 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $80.28 | 2023-2024 | Linzess |
| Merck Sharp & Dohme LLC | $61.36 | 2023-2024 | Dificid |
| Daiichi Sankyo INC. | $60.74 | 2022-2023 | Injectafer |
| Ardelyx, INC. | $49.98 | 2022-2024 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $48.62 | 2024 | Bylvay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $44.77 | 2023-2024 | Voquezna |
| Aimmune Therapeutics, INC. | $44.70 | 2024-2025 | Zenpep |
| Evoke Pharma, INC. | $43.33 | 2023 | Gimoti |
| Redhill Biopharma INC. | $43.13 | 2021-2022 | |
| Boston Scientific Corporation | $40.21 | 2024 | Watchman |
| Nestle Healthcare Nutrition INC. | $30.50 | 2021-2023 | |
| Celltrion USA INC. | $15.80 | 2024 | Vegzelma |
| Ferring Pharmaceuticals INC. | $14.83 | 2023 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melville Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.